Background and Goal: Inhaled corticosteroids (ICS) are commonly prescribed for chronic obstructive pulmonary disease (COPD), but not recommended as first-line treatment unless patients have asthma ...

Summary. Exacerbations of COPD are common and can be detrimental to both patient health and health care costs. Corticosteroids are recommended by consensus guidelines for patients during ...

Inhaled corticosteroids are often used outside of the recommended indications in COPD. Researchers revealed a link between long-term use and several risks for new diagnoses. Adults with COPD who ...

Significantly greater composite adverse outcome rates seen for long- vs short-term inhaled corticosteroid use for prevalent, inception cohorts. HealthDay News — For patients with chronic ...

Inhaled corticosteroids are often prescribed for chronic obstructive pulmonary disease but are not the first choice unless the patient has asthma-COPD overlap or frequent flare-ups. Chronic ...

The trial encompassed a broad range of COPD phenotypes and clinical presentations ... for use as an add-on treatment alongside intranasal corticosteroids for chronic rhinosinusitis with nasal ...

versus placebo in addition to inhaled triple therapy (dual long-acting bronchodilators plus inhaled corticosteroid) in 804 patients with COPD, a history of exacerbations, and evidence of type 2 ...

versus placebo in addition to inhaled triple therapy (dual long-acting bronchodilators plus inhaled corticosteroid) in 804 patients with COPD, a history of exacerbations, and evidence of type 2 ...

Considering all of the data and their limitations, questions still remain regarding the optimal treatment of COPD exacerbations ... reasonable to recommend oral corticosteroids when patient ...

Long-term inhaled corticosteroid (ICS) treatment in COPD patients is linked to increased adverse outcomes, including type 2 diabetes, cataracts, pneumonia, osteoporosis, and nontraumatic fractures.

The EMA has agreed to review GSK’s application to expand Nucala’s use as an add-on maintenance for individuals with COPD.